STOK
Stoke Therapeutics, Inc. operates as a biotechnology company. The Company develops antisense oligonucleotide medicines and therapies that increase target gene expression to treat diseases caused by loss of protein function. Stoke Therapeutics serves patients and customers in the United States.
Stoke Therapeutics, Inc. (STOK) is rated C (2.5/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Momentum (C). The rating has held at C for 13 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-15 | C+ (2.6) | C (2.4) | C+ (2.5) | C (2.3) | C+ (2.6) | C (2.5) |
| 2026-11-08 | C+ (2.6) | C (2.4) | C+ (2.5) | C (2.2) | C+ (2.6) | C (2.5) |
| 2026-11-01 | C+ (2.6) | C- (1.9) | C+ (2.7) | C (2.3) | C+ (2.7) | C (2.4) |
| 2026-10-25 | C+ (2.7) | C- (2.0) | C+ (2.6) | C- (2.0) | C+ (2.6) | C (2.4) |
| 2026-10-18 | C+ (2.7) | C- (2.0) | C+ (2.6) | C- (2.1) | C+ (2.6) | C (2.4) |